Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about Ascelia Pharma:
TOP STORIES
Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1
2025-04-16 17:55:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, [ …
TOP STORIES
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025
2025-03-18
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Company has received final minutes from [… …
TOP STORIES
Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting
2025-01-27 07:30:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two oral presentations and one scientific poster [&he …
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA SubmissionAnnual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study CompletionQ4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 StudyQuarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study